Compare CNK & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNK | STVN |
|---|---|---|
| Founded | 1984 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Containers/Packaging |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | 2007 | 2021 |
| Metric | CNK | STVN |
|---|---|---|
| Price | $33.81 | $17.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $33.70 | $25.67 |
| AVG Volume (30 Days) | ★ 2.2M | 320.1K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.24% | 0.39% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,115,000,000.00 | N/A |
| Revenue This Year | $11.01 | $9.67 |
| Revenue Next Year | $3.70 | $9.99 |
| P/E Ratio | ★ N/A | $27.15 |
| Revenue Growth | ★ 2.15 | N/A |
| 52 Week Low | $21.60 | $12.89 |
| 52 Week High | $34.40 | $28.00 |
| Indicator | CNK | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 68.26 | 50.18 |
| Support Level | $25.11 | $17.23 |
| Resistance Level | N/A | $19.41 |
| Average True Range (ATR) | 1.27 | 0.88 |
| MACD | 0.27 | -0.19 |
| Stochastic Oscillator | 89.59 | 36.29 |
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres. Cinemark manages its business under two reportable segments: U.S. markets and international markets. The majority of its revenue is generated from the U.S. markets segment.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.